```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 3219 Introduced in Senate (IS)]

<DOC>

118th CONGRESS
  1st Session
                                S. 3219

   To protect against seasonal and pandemic influenza, and for other 
                               purposes.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            November 2, 2023

Ms. Baldwin (for herself, Ms. Klobuchar, Mr. Blumenthal, and Ms. Smith) 
introduced the following bill; which was read twice and referred to the 
          Committee on Health, Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL

 
   To protect against seasonal and pandemic influenza, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Protecting America from Seasonal and 
Pandemic Influenza Act of 2023'' or the ``Influenza Act''.

SEC. 2. FINDINGS.

    Congress finds the following:
            (1) Influenza occurs seasonally each year, and, throughout 
        history, has caused devastating pandemics. The 1918 influenza 
        pandemic killed an estimated 675,000 people in the United 
        States.
            (2) In an average season, influenza results in 12,000 to 
        52,000 deaths in the United States, including over 100 
        pediatric deaths. Additionally, influenza causes hundreds of 
        thousands of hospitalizations and millions of illnesses.
            (3) The Council of Economic Advisors issued a report in 
        2019 estimating that seasonal influenza costs the United States 
        approximately $361,000,000,000 per year, and that an influenza 
        pandemic has the potential to cause up to $3,790,000,000,000 in 
        losses. This report was issued prior to the COVID-19 pandemic, 
        which will cost the United States an estimated 
        $16,000,000,000,000.
            (4) Most funding for pandemic influenza preparedness up 
        until fiscal year 2018 was derived from supplemental 
        appropriations that dated back to the 2009 H1N1 pandemic.
            (5) Centers for Disease Control and Prevention (referred to 
        in this section as the ``CDC'') studies of influenza 
        hospitalization rates by race and ethnicity during 10 influenza 
        seasons from 2009 to 2019 showed that individuals from racial 
        and ethnic minority groups are at higher risk for being 
        hospitalized with influenza.
            (6) The COVID-19 pandemic response has been built on the 
        pandemic influenza response ecosystem.
            (7) Strategies that increase seasonal influenza vaccination 
        rates will also improve pandemic readiness.
            (8) The National Influenza Vaccine Modernization Strategy 
        of 2020-2030 of the Department of Health and Human Services 
        should be implemented as quickly as possible to ensure the 
        Nation's vaccine enterprise is highly responsive, flexible, 
        scalable, and effective at reducing the impact of seasonal and 
        pandemic influenza viruses.
            (9) Influenza surveillance has been improved significantly 
        through advances in next-generation gene sequencing tools to 
        analyze circulating influenza viruses. The technology allows 
        the CDC to study more influenza viruses faster and in more 
        detail, and to monitor genetic changes in influenza viruses to 
        better understand and improve the effectiveness of influenza 
        vaccines.
            (10) Influenza diagnosis and surveillance has improved 
        significantly through advances in influenza testing. Timely 
        infection control and prevention strategies would be 
        significantly bolstered by accurate and readily accessible at-
        home diagnostic tests. Rapid diagnostics can improve access for 
        underserved populations and allow for better antibiotic 
        stewardship.
            (11) Vaccine hesitancy in the United States has reached a 
        tipping point where it is adversely affecting public health. 
        Misinformation is widely available on social media, and 
        traditional sources of information on the value and efficacy of 
        vaccines are not trusted by many people of the United States, 
        especially those who are vaccine hesitant.
            (12) Support for vaccine communication, outreach, and 
        administration across public health and health care settings is 
        critical to drive demand of influenza vaccines, treatments, and 
        medical countermeasures and ensure equitable uptake of such 
        innovations.

SEC. 3. STRENGTHENING AND DIVERSIFYING INFLUENZA VACCINE, THERAPEUTICS, 
              AND DIAGNOSTICS DEVELOPMENT, MANUFACTURING, AND SUPPLY 
              CHAIN.

    (a) Timely Delivery of First Doses of Finished Influenza Vaccine.--
            (1) National goal.--It is a national goal for the United 
        States to have, not later than 3 years after the date of 
        enactment of this Act, the capacity to deliver first doses of 
        finished influenza vaccine within 12 weeks of emergence of an 
        influenza strain with pandemic potential.
            (2) Plan.--Not later than 6 months after the date of 
        enactment of this Act, the Secretary of Health and Human 
        Services, acting through the Assistant Secretary for 
        Preparedness and Response and the Director of the Biomedical 
        Advanced Research and Development Authority, shall publish a 
        plan to achieve the goal specified in paragraph (1).
    (b) Universal Influenza Vaccine.--
            (1) National goal.--It is a national goal for the United 
        States to have developed a universal influenza vaccine, not 
        later than 10 years after the date of enactment of this Act.
            (2) Plan.--
                    (A) Publication.--Not later than 1 year after the 
                date of enactment of this Act, the Secretary of Health 
                and Human Services, acting through the Director of the 
                National Institutes of Health and the Director of the 
                Biomedical Advanced Research and Development Authority, 
                shall publish a plan to achieve the goal specified in 
                paragraph (1) in partnership with vaccine 
                manufacturers.
                    (B) Interim support.--The plan under subparagraph 
                (A) shall include provisions, as necessary to achieve 
                such goal, for support over the period of 5 years 
                following the publication of such plan of the 
                following:
                            (i) Incremental vaccine efficacy 
                        improvements.
                            (ii) The research workforce.
    (c) Strengthening the Vaccine Supply Chain.--
            (1) Public-private partnerships.--
                    (A) In general.--The Secretary of Health and Human 
                Services shall--
                            (i) establish public-private partnerships 
                        to strengthen the domestic vaccine supply 
                        chain; and
                            (ii) evaluate the capabilities, capacity, 
                        and utilization of such partnerships, including 
                        by assessing and testing relevant logistical 
                        and interoperable technology with stakeholders 
                        in the supply chain.
                    (B) Domestic vaccine supply chain.--For purposes of 
                this paragraph, the term ``domestic vaccine supply 
                chain'' includes the full domestic supply chain, 
                including--
                            (i) production of ingredients and 
                        manufacturing and distribution of finished 
                        vaccines;
                            (ii) fill-finish capacity; and
                            (iii) the supply chain of ancillary 
                        supplies such as needles and syringes.
            (2) Evaluation of using dpa.--The Secretary of Health and 
        Human Services, in coordination with the Administrator of the 
        Federal Emergency Management Agency and the Secretary of 
        Defense, shall--
                    (A) evaluate the use of the Defense Production Act 
                of 1950 (50 U.S.C. 4501 et seq.) for COVID-19 pandemic 
                response;
                    (B) not later than 1 year after the date of 
                enactment of this Act, complete such evaluation and 
                submit a report to Congress on the results of such 
                evaluation; and
                    (C) include in such report--
                            (i) recommendations on using the Defense 
                        Production Act of 1950 (50 U.S.C. 4501 et seq.) 
                        for building domestic capacity to respond to an 
                        influenza pandemic; and
                            (ii) input from external stakeholders.
    (d) National Influenza Vaccine Modernization Strategy.--The 
Secretary of Health and Human Services shall--
            (1) implement the portions of the National Influenza 
        Vaccine Modernization Strategy 2020-2030 that are within the 
        authority of the Department of Health and Human Services to 
        carry out (under other applicable provisions of law); and
            (2) by June 15 each calendar year through 2030, submit to 
        Congress a report on such implementation.
    (e) Assistant Secretary for Preparedness and Response.--Section 
2811 of the Public Health Service Act (42 U.S.C. 300hh-10) is amended--
            (1) in subsection (b)--
                    (A) in paragraph (3), by inserting ``, including 
                the pandemic influenza medical countermeasures program 
                under paragraphs (2)(E) and (4)(H) of section 319L(c)'' 
                after ``qualified pandemic or epidemic products (as 
                defined in section 319F-3)''; and
                    (B) in paragraph (7), in the matter preceding 
                subparagraph (A), by inserting ``, including through 
                the pandemic influenza medical countermeasures program 
                under paragraphs (2)(E) and (4)(H) of section 319L(c)'' 
                after ``for each such threat''; and
            (2) in subsection (d)(2)--
                    (A) in subparagraph (J)(v), by striking ``and'' at 
                the end;
                    (B) by redesignating subparagraph (K) as 
                subparagraph (L); and
                    (C) by inserting after subparagraph (J) the 
                following:
                    ``(K) evaluate progress with respect to 
                implementing the National Influenza Vaccine 
                Modernization Strategy, issued in June 2020, or any 
                successor strategy; and''.
    (f) Biomedical Advanced Research and Development Authority.--
            (1) Preparedness activities.--Section 319L(c) of the Public 
        Health Service Act (42 U.S.C. 247d-7e(c)) is amended--
                    (A) in paragraph (2)--
                            (i) in subparagraph (C), by striking 
                        ``and'' at the end;
                            (ii) in subparagraph (D), by striking the 
                        period at the end and inserting ``; and''; and
                            (iii) by adding at the end of the 
                        following:
                    ``(E) supporting pandemic influenza countermeasure 
                preparedness.''; and
                    (B) in paragraph (4), by adding at the end of the 
                following:
                    ``(H) Pandemic influenza medical countermeasures 
                program.--In carrying out paragraph (2)(E), the 
                Secretary shall establish and implement a program 
                that--
                            ``(i) supports research and development 
                        activities for qualified pandemic or epidemic 
                        products (as defined in section 319F-3), 
                        including by--
                                    ``(I) developing innovative 
                                technologies to enhance rapid response 
                                to pandemic influenza threats;
                                    ``(II) developing influenza 
                                vaccines with potential universal 
                                vaccination capability;
                                    ``(III) developing enhanced 
                                influenza vaccines with longer lasting 
                                broad spectrum protective immunity 
                                against a wider range of antigenically 
                                divergent influenza strains;
                                    ``(IV) developing alternative 
                                vaccine delivery approaches;
                                    ``(V) developing novel small- and 
                                large-molecule novel influenza 
                                antivirals, monoclonal antibodies, and 
                                other products that provide better 
                                influenza treatment and prevention;
                                    ``(VI) developing innovative 
                                technologies to enhance rapid diagnosis 
                                of influenza; and
                                    ``(VII) implementing the National 
                                Influenza Vaccine Modernization 
                                Strategy, issued in June 2020, or any 
                                successor strategy;
                            ``(ii) ensures readiness to respond to 
                        qualified pandemic and epidemic threats, 
                        including by--
                                    ``(I) supporting development and 
                                manufacturing of influenza virus seeds, 
                                clinical trial lots, and stockpiles of 
                                novel influenza strains;
                                    ``(II) supporting the stockpile of 
                                influenza antivirals through 
                                diversifying and replenishing the 
                                existing stockpile of influenza 
                                antivirals;
                                    ``(III) supporting manufacturing 
                                and fill-finish rapid response 
                                infrastructure;
                                    ``(IV) supporting the stockpile of 
                                influenza testing equipment and 
                                supplies; and
                                    ``(V) testing and evaluating 
                                pandemic threat rapid response 
                                capabilities through regular 
                                preparedness drills with key public and 
                                private sector partners that examine 
                                the range of activities (including 
                                production and clinical testing of 
                                influenza diagnostics, vaccines, and 
                                therapeutics) required to effectively 
                                respond to novel threats; and
                            ``(iii) builds, sustains, and replenishes 
                        qualified pandemic and epidemic stockpiles of 
                        bulk antigen and adjuvant material, including 
                        by--
                                    ``(I) annually testing the potency 
                                and shelflife potential of all existing 
                                pandemic and epidemic stockpiles held 
                                by the Department of Health and Human 
                                Services; and
                                    ``(II) developing, and 
                                disseminating to key public and private 
                                sector partners, a life cycle 
                                management plan.''.
    (g) Authorization of Appropriations.--Section 319L(d) of the Public 
Health Service Act (42 U.S.C. 247d-7e(d)) is amended by adding at the 
end the following:
            ``(3) Pandemic influenza.--To carry out this section and 
        section 2811 with respect to pandemic influenza, in addition to 
        amounts authorized to be appropriated by paragraph (2) and any 
        amounts authorized to be appropriated by section 2811, there is 
        authorized to be appropriated $335,000,000 for each of fiscal 
        years 2024 through 2028, to remain available until expended.''.

SEC. 4. PROMOTING INNOVATIVE APPROACHES AND USE OF NEW TECHNOLOGIES TO 
              DETECT, PREVENT, AND RESPOND TO INFLUENZA.

    (a) Sense of Congress.--It is the sense of Congress that the 
Centers for Disease Control and Prevention should support interoperable 
immunization information systems that enable bidirectional data 
exchange among States, localities, and community immunization 
providers.
    (b) Prioritizing Influenza, Influenza Combination, and Pathogen 
Agnostic Tools.--
            (1) NIH.--The Director of the National Institutes of Health 
        may conduct or support basic research prioritizing the 
        development of--
                    (A) agnostic tools to detect influenza and other 
                pathogens; and
                    (B) technologies that automate sample preparation 
                for such tools.
            (2) BARDA.--The Director of the Biomedical Advanced 
        Research and Development Authority may conduct or support 
        advanced development of novel sequencing modalities 
        prioritizing tools described in paragraph (1)(A) and 
        technologies described in paragraph (1)(B).
    (c) Development of Point-of-Care and Self-Testing Diagnostics.--The 
Director of the Biomedical Advanced Research and Development Authority, 
in collaboration with the Director of the Centers for Disease Control 
and Prevention, the Director of the National Institutes of Health, and 
the Commissioner of Food and Drugs, may conduct or support development 
of rapid, accurate, easily accessible, self-administrable diagnostic 
tests that are readable at the point of care or at home.
    (d) Incorporating Diagnostics Supply Chain Resiliency Into 
Influenza Pandemic Planning.--The Assistant Secretary for Preparedness 
and Response, in collaboration with the Commissioner of Food and Drugs, 
the Director of the Centers for Disease Control and Prevention, the 
Secretary of Commerce, and the Secretary of Transportation, shall--
            (1) incorporate diagnostics supply chain resiliency into 
        influenza pandemic planning that supports a health care system 
        that tests to treat and bolsters testing and vaccine delivery 
        supply chains; and
            (2) not later than 1 year after the date of enactment of 
        this Act, publish a plan for rapidly expanding public and 
        private diagnostic testing capacity (including at clinical 
        laboratories, at public health department laboratories, and by 
        means of self-testing) in an influenza pandemic, including 
        addressing transportation infrastructure, the need for 
        sterilization, and sourcing critical raw materials, components, 
        and parts.
    (e) Scaling up Prophylactic Influenza Antibody Products That 
Address Gaps in Coverage.--The Director of the Biomedical Advanced 
Research and Development Authority may conduct or support preventive 
approaches, including those still in preclinical and clinical stages, 
to rapidly scale up preexposure prophylactic influenza antibody 
products that address influenza infection.
    (f) Modernizing Potency Assays.--The Commissioner of Food and Drugs 
shall work with vaccine manufacturers to modernize potency assays 
across a variety of manufacturing technologies so as to reduce by 6 
weeks the period required to first evaluate new vaccine candidates 
during a pandemic.
    (g) Improved Influenza Therapeutics.--The Director of the 
Biomedical Advanced Research and Development Authority may conduct or 
support improved influenza therapeutics that--
            (1) are more broadly protective; and
            (2) meet the needs of high-risk and high-exposure patients.

SEC. 5. INCREASING INFLUENZA VACCINE, THERAPEUTICS, AND TESTING ACCESS 
              AND COVERAGE ACROSS ALL POPULATIONS.

    (a) Annual Report on Public Communication Strategy.--The Director 
of the Centers for Disease Control and Prevention shall submit an 
annual report to Congress on the public communication strategy of the 
Centers to increase public confidence in the safety and effectiveness 
of vaccines.
    (b) Sense of Congress.--It is the sense of Congress that the 
Director of the National Institutes of Health, the Director of the 
Centers for Disease Control and Prevention, the Secretary of Defense, 
the Secretary of Veterans Affairs, the Administrator of the Centers for 
Medicare & Medicaid Services, and the Commissioner of Food and Drugs 
should support research using large data sets from multiple sources of 
health data to further support and evaluate vaccine safety and 
effectiveness over multiple influenza seasons.
    (c) Addressing Misinformation and Disinformation.--
            (1) In general.--The Secretary of Health and Human Services 
        shall create partnerships to address misinformation and 
        disinformation with respect to influenza vaccines.
            (2) Requirements.--The partnerships under paragraph (1) 
        shall--
                    (A) build on lessons learned from COVID-19; and
                    (B) allow for dissemination of best practices and 
                lessons learned between partnering organizations.
            (3) Members.--The members of the partnerships under 
        paragraph (1) shall include representatives of organizations 
        with experience working with vulnerable populations, 
        including--
                    (A) individuals with chronic health conditions;
                    (B) older individuals;
                    (C) parents of young children;
                    (D) pregnant people;
                    (E) Tribal communities; and
                    (F) racial and ethnic minorities.
            (4) Conferring with partnering organizations.--The 
        Secretary of Health and Human Services shall confer with 
        organizations represented in partnerships under paragraph (1)--
                    (A) in advance of each seasonal influenza season, 
                on messaging and communications; and
                    (B) at the end of each seasonal influenza season, 
                on best practices and lessons learned.
            (5) Report to congress.--Not later than one year after the 
        date of enactment of this Act, the Secretary of Health and 
        Human Services shall report to Congress on the partnerships 
        created, and activities conducted, under this section.
    (d) Communications Public-Private Partnership.--
            (1) In general.--Not later than 6 months after the date of 
        enactment of this Act, the Secretary of Health and Human 
        Services shall implement a targeted demonstration project that 
        provides for the establishment of a communications public-
        private partnership initiative for increasing vaccine 
        confidence.
            (2) Requirements.--The demonstration project under 
        paragraph (1) shall--
                    (A) be implemented through an independent, 
                nongovernmental, nonprofit entity;
                    (B) focus on individuals with chronic illness or 
                other comorbidities who tend to have worse clinical 
                outcomes from influenza (such as individuals with heart 
                disease or diabetes, and racial and ethnic minorities);
                    (C) support behavioral research around sources of 
                vaccine hesitancy; and
                    (D) develop and implement a targeted, multimodal 
                communications campaign, using internet platforms, 
                television, and nontraditional targeted social media 
                and community outreach in an effort to reach 
                individuals who may be especially vaccine hesitant.
            (3) Report.--Not later than 6 months after completion of 
        the demonstration project under paragraph (1), the Secretary of 
        Health and Human Services shall--
                    (A) prepare a report on the demonstration project, 
                including an evaluation of the project's methods, 
                findings, and results; and
                    (B) make such report publicly available on the 
                website of the Department of Health and Human Services.
    (e) Incorporating Health Equity Into Seasonal and Pandemic 
Influenza Planning and Response.--The Director of the Centers for 
Disease Control and Prevention and the Assistant Secretary for 
Preparedness and Response shall--
            (1) incorporate health equity into the seasonal and 
        pandemic influenza planning and response programs overseen by 
        such officials; and
            (2) in so doing--
                    (A) emphasize the inclusion of all populations; and
                    (B) include strategies to reach communities of 
                color, communities with lower socioeconomic status, 
                seniors, and individuals with disabilities, including 
                addressing barriers to vaccinations, therapeutics, and 
                diagnostics in the point-of-care and at-home self-
                testing settings.
    (f) Expanding Access to Influenza Treatment and Adopting Lessons 
Learned From COVID-19 Federal Retail Pharmacy Program.--
            (1) Report.--Not later than 6 months after the date of 
        enactment of this Act, the Secretary of Health and Human 
        Services shall submit a report to the Congress on lessons 
        learned from the COVID-19 Federal Retail Pharmacy Program, 
        including aspects of the program that could be applied with 
        respect to multianalyte tests that target COVID-19 as well as 
        influenza and other upper respiratory viruses.
            (2) Demonstration project.--
                    (A) In general.--Not later than one year after the 
                date of enactment of this Act, the Secretary of Health 
                and Human Services shall initiate an influenza test-to-
                treat demonstration project that builds on the test-to-
                treat model employed for COVID-19.
                    (B) Length; locations.--This demonstration project 
                under subparagraph (A) shall run for the length of one 
                seasonal influenza season and be based in one or more 
                of the following locations:
                            (i) Facilities that serve vulnerable 
                        populations, such as populations who are in 
                        long-term care facilities, are 65 years of age 
                        or older, may have other medical conditions, 
                        and will be in unavoidable close contact with 
                        others.
                            (ii) Federal health care facilities that 
                        serve at-risk and vulnerable communities, such 
                        as Indian Health Service clinics, Federally 
                        qualified health centers (as defined in section 
                        1861(aa) of the Social Security Act (42 U.S.C. 
                        1395x(aa))), and facilities of the Department 
                        of Veterans Affairs.
                            (iii) Existing COVID-19 test-to-treat sites 
                        at retail pharmacies, potentially in specific 
                        geographic areas with historically high 
                        mortality from influenza.
                            (iv) Other appropriate locations identified 
                        by the Secretary of Health and Human Services, 
                        in consultation with external stakeholder 
                        organizations, to test the operational 
                        feasibility and impact of influenza test-to-
                        treat programs.
            (3) Report.--Not later than 6 months after completion of 
        the demonstration project under paragraph (2), the Secretary of 
        Health and Human Services shall--
                    (A) prepare a report on the demonstration project 
                under paragraph (2), including an evaluation of the 
                project's methods, findings, and results; and
                    (B) make such report publicly available on the 
                website of the Department of Health and Human Services.
    (g) Creating Administration Pathways.--The Secretary of Health and 
Human Services may award grants to States to create administration 
pathways for pharmacy personnel to administer influenza vaccines, 
tests, and therapeutics, in order to increase vaccination, testing, and 
relevant treatment as needed for adults and children.
    (h) Strategic National Stockpile.--The Secretary of Health and 
Human Services shall incorporate into the Strategic National Stockpile 
under section 319F-2 of the Public Health Service Act (42 U.S.C. 247d-
6b) products needed to respond to pandemic influenza, including 
through--
            (1) dynamic management of antivirals;
            (2) vendor-managed inventory of testing equipment and 
        supplies;
            (3) replenishment of aging antivirals, testing equipment, 
        supplies, and other products; and
            (4) diversification of stockpiled products.
    (i) Monitoring and Distributing Influenza Antiviral Supplies.--The 
Secretary of Health and Human Services shall--
            (1) monitor influenza antiviral supplies throughout the 
        country and publicly report challenges in availability in any 
        region, State, county, or metropolitan area; and
            (2) establish a process, to be used in the case of a 
        pandemic or during times when influenza antiviral supply 
        availability is challenged, to ensure rapid and effective 
        distribution of products to areas of urgent need in close 
        coordination with manufacturers, distributors, and State and 
        local health officials.
    (j) Plan for Ensuring Access to Appropriate Influenza Therapeutics, 
Preexposure Prophylaxis, and Diagnostics.--
            (1) In general.--Not later than 1 year after the date of 
        enactment of this Act, the Secretary of Health and Human 
        Services shall publish a plan for ensuring access to 
        appropriate influenza therapeutics, preexposure prophylaxis 
        influenza antibody products, and influenza diagnostics, 
        including during times when availability is challenged in 
        certain regions or localities, for--
                    (A) high-risk patients, such as nursing home and 
                pediatric patients;
                    (B) high-exposure patients, such as first 
                responders and health care workers; and
                    (C) low-income individuals, individuals covered 
                under the Medicaid program under title XIX of the 
                Social Security Act (42 U.S.C. 1396 et seq.), uninsured 
                individuals, Tribal communities, and other underserved 
                populations.
            (2) Communications efforts.--The plan required by paragraph 
        (1) shall include communications efforts to educate the public 
        about the benefits of early use of influenza diagnostics, 
        therapeutics. and preexposure prophylaxis products.
    (k) GAO Review on Transferring COVID-19 Technologies.--
            (1) In general.--Not later than 6 months after the date of 
        enactment of this Act, the Comptroller General of the United 
        States shall conduct a review of the technology and systems 
        utilized by the Centers for Disease Control and Prevention, the 
        Administration for Strategic Preparedness and Response, 
        Operation Warp Speed, the Countermeasure Acceleration Group, H-
        CORE, and other current and historical departments and agencies 
        involved in the COVID-19 response for surveillance and tracking 
        of COVID-19 cases, treatments, and vaccines, with particular 
        focus on--
                    (A) disease surveillance;
                    (B) vaccine surveillance; and
                    (C) vaccine effectiveness.
            (2) Scope.--The review under paragraph (1) shall include--
                    (A) assessment of which technology and systems can 
                be applied to, or can be altered to apply to, influenza 
                and other infectious diseases; and
                    (B) formulation of recommendations for applying and 
                altering technologies and systems as described in 
                subparagraph (A).
            (3) Report by hhs to congress.--Not later than 30 days 
        after completion of the review required by paragraph (1), the 
        Secretary of Health and Human Services shall submit a report to 
        Congress on the timeline and actions necessary to implement the 
        recommendations formulated under paragraph (2)(B).

SEC. 6. AUTHORIZING SUSTAINABLE FUNDING FOR THE INFLUENZA ECOSYSTEM.

    (a) Influenza Planning and Response Program.--There is authorized 
to be appropriated $231,000,000 for fiscal year 2024 and each 
subsequent fiscal year for programs and activities of the Centers for 
Disease Control and Prevention relating to influenza planning and 
response.
    (b) Strategic National Stockpile.--There is authorized to be 
appropriated $965,000,000 for fiscal year 2024 and each subsequent 
fiscal year for the Strategic National Stockpile under section 319F-2 
of the Public Health Service Act (42 U.S.C. 247d-6b).
    (c) Hospital Preparedness Program.--There is authorized to be 
appropriated $305,000,000 for fiscal year 2024 and each subsequent 
fiscal year for Hospital Preparedness Program of the Assistant 
Secretary for Preparedness and Response.
    (d) Universal Flu Vaccine Research.--There is authorized to be 
appropriated $270,000,000 for fiscal year 2024 and each subsequent 
fiscal year for research of the National Institutes of Health to 
develop a universal flu vaccine.
    (e) Immunization Program.--There is authorized to be appropriated 
$682,000,000 for fiscal year 2024 and each subsequent fiscal year for 
the immunization program of the Centers for Disease Control and 
Prevention under section 317 of the Public Health Service Act (42 
U.S.C. 247b).
    (f) Public Health Emergency Preparedness Program.--There is 
authorized to be appropriated $735,000,000 for fiscal year 2024 and 
each subsequent fiscal year for the Public Health Emergency 
Preparedness Program of the Centers for Disease Control and Prevention.
    (g) Infectious Disease Rapid Response Reserve Fund.--There is 
authorized to be appropriated $35,000,000 for fiscal year 2024 and each 
subsequent fiscal year for the Infectious Disease Rapid Response 
Reserve Fund of the Centers for Disease Control and Prevention.
    (h) Data Modernization Initiative.--There is authorized to be 
appropriated $175,000,000 for fiscal year 2024 and each subsequent 
fiscal year for the Public Health Data Modernization Initiative of the 
Centers for Disease Control and Prevention.
                                 <all>
```